Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
NCT00285428 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 82
Last updated 2021-08-17
Summary
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
Conditions
- Non-Hodgkin's Lymphoma
Interventions
- DRUG
-
hA20-humanized anti-CD20 antibody
once weekly iv dosing for 4 weeks
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
William Wegener, MD, PhD · Gilead Sciences
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-09-30
- Primary Completion
- 2007-10-31
- Completion
- 2007-10-31
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05201248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
NCT00004858 ·Status: UNKNOWN ·Phase: PHASE1
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
NCT00003204 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab in Treating Patients With Hodgkin's Lymphoma
NCT00003820 ·Status: COMPLETED ·Phase: PHASE2
-
RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT03485118 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
NCT00290498 ·Status: COMPLETED ·Phase: PHASE2
-
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
NCT00438880 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
NCT00816959 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
NCT00017290 ·Status: UNKNOWN ·Phase: PHASE3
-
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
NCT04022980 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05623982 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
NCT01828008 ·Status: UNKNOWN
-
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
NCT04526834 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
NCT00412321 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
NCT00398372 ·Status: COMPLETED ·Phase: NA
-
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
NCT00003605 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
NCT00022893 ·Status: UNKNOWN ·Phase: NA
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
NCT00003150 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
NCT00061425 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma
NCT01459887 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
NCT00028717 ·Status: UNKNOWN ·Phase: PHASE3
-
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
NCT00088881 ·Status: TERMINATED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma
NCT01209871 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00278408 ·Status: COMPLETED ·Phase: PHASE3
-
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
NCT04028440 ·Status: UNKNOWN ·Phase: EARLY_PHASE1